Positrigo, a Swiss based company developing nuclear medical devices to advance functional brain imaging, today announced the closing of a new financing round of 7 million CHF and the appointment of new board members. This financing was oversubscribed and brings reinforcement to Positrigo’s shareholding structure with lead investor HealthCap, a major European venture capital player in the life sciences space and Navivo, a venture capital fund supporting European tech companies in their global expansion. They were joined by existing shareholders and several family offices and individuals who are continuously supporting the company’s growth. The funds are instrumental to support production and accelerate the commercialization of the NeuroLF system – a dedicated brain Positron Emission Tomography (PET) device - which is the first product of its kind with market clearance in the US and EU.

Strong New Investor Group
“We are thrilled to have closed this financing round with a well-known and established European venture capital firm like HealthCap. Not only will it allow us to accelerate our commercial efforts in the US and EU but it is also testament for the strong business opportunity that lies ahead of us,” says Jannis Fischer, CEO and co-founder of Positrigo. “The NeuroLF system is used for the diagnosis of brain related disorders including brain tumors, epilepsy or movement disorders like Parkinson’s disease. However, the strongest demand for brain PET we see in the diagnosis of Alzheimer’s disease (AD) which is the most common form of dementia, accounting for ~70% of all dementias in those over 60. In 2023 there were over 55 million people worldwide living with dementia and it is predicted that individuals affected by AD will grow to 150 million in 2050. This investment allows us to capture this market opportunity by making brain PET imaging much more widely accessible than it is today.”


Max Odlander, partner at HealthCap, will represent the firm and support Positrigo by joining as a new board member. “I am deeply impressed by what Positrigo accomplished already in a relatively short period of time and with limited resources. Beside the highly committed team, we believe that their imaging solution and the latest developments in the treatment of AD patients offers an exciting business opportunity. We are very excited to be part of it and to offer our support.”

New Board Members
Beside Max Odlander, Positrigo is further strengthened by the appointment of two new independent board members. Mr. Didier Deltort is currently a Senior Advisor at several Venture Capital and Private Equity firms. With over 30 years of global experience in healthcare technology, he has held leadership roles at GE Healthcare, Zimmer Biomet, Boston Scientific, and HP Inc. At GE Healthcare, he spearheaded innovations in diagnostic imaging and patient monitoring, while at Zimmer Biomet he was overseeing the EMEA marketing, sales, and distribution of musculoskeletal products, including surgical robotics solutions. Dr. Ajit Singh is a partner and managing director at Artiman Ventures, based in Palo Alto, California. Prior to Artiman, he was the CEO of BioImagene – an Oncology diagnostics startup that was acquired by Roche in 2010. Earlier, he worked at Siemens for twenty years in the US and in Germany, the most recent ten years in global CEO roles for Siemens Oncology and Siemens Digital Imaging. Dr. Singh is an adjunct professor at the Stanford University School of Medicine, as well as a Trustee of the American Association for Cancer Research (AACR) Foundation.

Most Read Announcements Homepage